Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30748-6. doi: 10.1016/j.eururo.2018.10.007. [Epub ahead of print]

PMID:
30318330
3.

Renal cell carcinoma: standards and controversies.

Klatte T, Stewart GD.

World J Urol. 2018 Sep 12. doi: 10.1007/s00345-018-2490-5. [Epub ahead of print] No abstract available.

PMID:
30209553
4.

Genomics and clinical correlates of renal cell carcinoma.

Mitchell TJ, Rossi SH, Klatte T, Stewart GD.

World J Urol. 2018 Aug 11. doi: 10.1007/s00345-018-2429-x. [Epub ahead of print]

PMID:
30099580
5.

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.

Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ, Ferdinand JR, Collord G, Botting RA, Popescu DM, Loudon KW, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Del Castillo Velasco-Herrera M, Guzzo C, Richoz N, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Maxwell PH, Lindsay S, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Clatworthy M, Behjati S.

Science. 2018 Aug 10;361(6402):594-599. doi: 10.1126/science.aat1699.

PMID:
30093597
6.

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Aug 1. doi: 10.1007/s00345-018-2427-z. [Epub ahead of print]

PMID:
30069581
7.

Quality of life outcomes in patients with localised renal cancer: a literature review.

Rossi SH, Klatte T, Stewart GD.

World J Urol. 2018 Jul 26. doi: 10.1007/s00345-018-2415-3. [Epub ahead of print]

PMID:
30051264
8.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

9.

NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis.

Rodrigues P, Patel SA, Harewood L, Olan I, Vojtasova E, Syafruddin SE, Zaini MN, Richardson EK, Burge J, Warren AY, Stewart GD, Saeb-Parsy K, Samarajiwa SA, Vanharanta S.

Cancer Discov. 2018 Jul;8(7):850-865. doi: 10.1158/2159-8290.CD-17-1211. Epub 2018 Jun 6.

PMID:
29875134
10.

Prognostic factors and prognostic models for renal cell carcinoma: a literature review.

Klatte T, Rossi SH, Stewart GD.

World J Urol. 2018 Apr 30. doi: 10.1007/s00345-018-2309-4. [Epub ahead of print] Review.

PMID:
29713755
11.

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):611-623.e17. doi: 10.1016/j.cell.2018.02.020. Epub 2018 Apr 12.

12.

Epidemiology and screening for renal cancer.

Rossi SH, Klatte T, Usher-Smith J, Stewart GD.

World J Urol. 2018 Sep;36(9):1341-1353. doi: 10.1007/s00345-018-2286-7. Epub 2018 Apr 2. Review.

13.

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol Focus. 2018 Mar 7. pii: S2405-4569(18)30072-5. doi: 10.1016/j.euf.2018.02.010. [Epub ahead of print]

PMID:
29525381
14.

Allosteric interactions between GABAB1 subunits control orthosteric binding sites occupancy within GABAB oligomers.

Stewart GD, Comps-Agrar L, Nørskov-Lauritsen LB, Pin JP, Kniazeff J.

Neuropharmacology. 2018 Jul 1;136(Pt A):92-101. doi: 10.1016/j.neuropharm.2017.12.042. Epub 2018 Jan 2.

PMID:
29305121
15.

Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.

Klatte T, Fife K, Welsh SJ, Sachdeva M, Armitage JN, 'Aho T, Riddick AC, Matakidou A, Eisen T, Stewart GD.

World J Urol. 2018 Mar;36(3):417-425. doi: 10.1007/s00345-017-2154-x. Epub 2017 Dec 18.

PMID:
29256020
16.

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Figlin RA, Leibovich BC, Stewart GD, Negrier S.

Ann Oncol. 2018 Feb 1;29(2):324-331. doi: 10.1093/annonc/mdx743.

PMID:
29186296
17.

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

Stewart GD, Leibovich BC, Negrier S, Figlin RA.

J Clin Oncol. 2017 Dec 10;35(35):3895-3897. doi: 10.1200/JCO.2017.75.4242. Epub 2017 Oct 25. No abstract available.

PMID:
29068785
18.

Management of a Renal Mass in a Solitary Kidney: To Freeze or To Cut?

Klatte T, Riddick ACP, Stewart GD.

Eur Urol. 2018 Feb;73(2):260-261. doi: 10.1016/j.eururo.2017.09.023. Epub 2017 Oct 9. No abstract available.

PMID:
29032847
19.

Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.

Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M, Tomkins S, Stewart GD, Park SM, Woodward ER, Maher ER.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562. Review.

20.

Quantitative mechanical assessment of the whole prostate gland ex vivo using dynamic instrumented palpation.

Hammer SJ, Good DW, Scanlan P, Palacio-Torralba J, Phipps S, Stewart GD, Shu W, Chen Y, McNeill SA, Reuben RL.

Proc Inst Mech Eng H. 2017 Dec;231(12):1081-1100. doi: 10.1177/0954411917734257. Epub 2017 Sep 30.

PMID:
28965486
21.

European temporal trends in the use of lymph node dissection in patients with renal cancer.

Capitanio U, Stewart GD, Larcher A, Ouzaid I, Akdogan B, Roscigno M, Marszalek M, Dell'Oglio P, Salagierski M, Volpe A, Mir MC, Kriegmair M, Terrone C, Brookman-May SD, Montorsi F, Klatte T; Kidney Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU).

Eur J Surg Oncol. 2017 Nov;43(11):2184-2192. doi: 10.1016/j.ejso.2017.07.016. Epub 2017 Aug 3.

PMID:
28801061
22.

Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.

Blick C, Ritchie AWS, Eisen T, Stewart GD.

Nat Rev Urol. 2017 Dec;14(12):753-759. doi: 10.1038/nrurol.2017.123. Epub 2017 Aug 1. Review.

PMID:
28762388
23.

Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?

Capitanio U, Stewart GD, Klatte T, Akdogan B, Roscigno M, Marszalek M, Dell'Oglio P, Zaffuto E, Rodriguez Faba O, Salagierski M, Lingard J, Carini M, Ouzaid I, Mir MC, Montorsi F, Da Pozzo LF, Stief C, Minervini A, Brookman-May SD.

Eur Urol Focus. 2017 Mar 21. pii: S2405-4569(17)30068-8. doi: 10.1016/j.euf.2017.02.020. [Epub ahead of print]

PMID:
28753867
24.

A novel method for rapid and quantitative mechanical assessment of soft tissue for diagnostic purposes: A computational study.

Palacio-Torralba J, Good DW, Stewart GD, McNeill SA, Reuben RL, Chen Y.

Int J Numer Method Biomed Eng. 2018 Feb;34(2). doi: 10.1002/cnm.2917. Epub 2017 Aug 23.

25.

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G.

Eur Urol Focus. 2016 Dec 15;2(6):582-588. doi: 10.1016/j.euf.2017.04.002. Epub 2017 Apr 20. Review.

PMID:
28723489
26.

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer.

Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ, Overton IM.

BMC Med. 2017 Jun 26;15(1):118. doi: 10.1186/s12916-017-0874-9.

27.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
28.

Different Successful Management Strategies for Obstructing Renal Parapelvic Cysts.

Rossi SH, Koo B, Riddick A, Shah N, Stewart GD.

Urol Int. 2018;101(3):366-368. doi: 10.1159/000475886. Epub 2017 May 12.

PMID:
28494441
29.

Meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography.

Rossi SH, Hsu R, Blick C, Goh V, Nathan P, Nicol D, Fleming S, Sweeting M, Wilson EC, Stewart GD.

Br J Surg. 2017 May;104(6):648-659. doi: 10.1002/bjs.10523. Review.

PMID:
28407225
30.

Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome.

Van Neste C, Laird A, O'Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ, Stewart GD, De Meyer T.

Cell Oncol (Dordr). 2017 Jun;40(3):293-297. doi: 10.1007/s13402-016-0313-5. Epub 2017 Jan 10.

PMID:
28074387
31.

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.

Gremel G, Djureinovic D, Niinivirta M, Laird A, Ljungqvist O, Johannesson H, Bergman J, Edqvist PH, Navani S, Khan N, Patil T, Sivertsson Å, Uhlén M, Harrison DJ, Ullenhag GJ, Stewart GD, Pontén F.

BMC Cancer. 2017 Jan 4;17(1):9. doi: 10.1186/s12885-016-3030-6.

32.

Striated Muscle in Radical Prostatectomy Specimens: A Marker of Apical Dissection Quality and an Independent Predictor of Urinary Continence after Endoscopic Extraperitoneal Radical Prostatectomy.

Good DW, Wood A, Stewart L, Stolzenburg JU, Ganzer R, Neuhaus J, Stewart GD, McNeill SA.

Urol Int. 2017;98(1):71-78. doi: 10.1159/000452632. Epub 2016 Nov 26.

PMID:
27889781
33.

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Méjean A, Nathan P, Oades G, Patard JJ, Paul J, Ravaud A, Escudier B; Renal Cross Channel Group.

Eur Urol. 2017 Jun;71(6):845-847. doi: 10.1016/j.eururo.2016.10.029. Epub 2016 Nov 1.

PMID:
27815086
34.

Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids.

Jamieson LE, Camus VL, Bagnaninchi PO, Fisher KM, Stewart GD, Nailon WH, McLaren DB, Harrison DJ, Campbell CJ.

Nanoscale. 2016 Sep 22;8(37):16710-16718.

PMID:
27714168
35.

Correction: Measuring the effects of fractionated radiation therapy in a 3D prostate cancer model system using SERS nanosensors.

Camus VL, Stewart GD, Nailon WH, McLaren DB, Campbell CJ.

Analyst. 2016 Oct 3;141(20):5900.

PMID:
27704094
36.

Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90.

Henke A, Franco OE, Stewart GD, Riddick AC, Katz E, Hayward SW, Thomson AA.

Cancers (Basel). 2016 Aug 24;8(9). pii: E77. doi: 10.3390/cancers8090077.

37.

Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Sengmany K, Singh J, Stewart GD, Conn PJ, Christopoulos A, Gregory KJ.

Neuropharmacology. 2017 Mar 15;115:60-72. doi: 10.1016/j.neuropharm.2016.07.001. Epub 2016 Jul 5.

38.

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.

Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W.

Prostate. 2016 Sep;76(12):1078-87. doi: 10.1002/pros.23191. Epub 2016 Apr 28.

39.

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.

Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F, Trooskens G, Van Criekinge W, De Meyer T, Harrison DJ.

Oncotarget. 2016 May 3;7(18):25241-50. doi: 10.18632/oncotarget.8308.

40.

Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants.

Rueda P, Harley E, Lu Y, Stewart GD, Fabb S, Diepenhorst N, Cremers B, Rouillon MH, Wehrle I, Geant A, Lamarche G, Leach K, Charman WN, Christopoulos A, Summers RJ, Sexton PM, Langmead CJ.

PLoS One. 2016 Jan 19;11(1):e0146846. doi: 10.1371/journal.pone.0146846. eCollection 2016.

41.

Current Status of Focal Cryoablation for Small Renal Masses.

Rodriguez Faba O, Akdogan B, Marszalek M, Langenhuijsen JF, Brookman-May S, Stewart GD, Capitanio U, Sanguedolce F; Renal Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU).

Urology. 2016 Apr;90:9-15. doi: 10.1016/j.urology.2015.11.041. Epub 2015 Dec 29. Review.

PMID:
26743392
42.

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM; Renal Cross Channel Group.

Urol Oncol. 2016 Apr;34(4):167.e17-23. doi: 10.1016/j.urolonc.2015.10.015. Epub 2015 Dec 3.

PMID:
26670200
43.

Frozen section during partial nephrectomy: an unreliable test that changes nothing?

Stewart GD, Oades G.

BJU Int. 2015 Dec;116(6):836-7. doi: 10.1111/bju.13046. No abstract available.

44.

Patient specific modeling of palpation-based prostate cancer diagnosis: effects of pelvic cavity anatomy and intrabladder pressure.

Palacio-Torralba J, Jiménez Aguilar E, Good DW, Hammer S, McNeill SA, Stewart GD, Reuben RL, Chen Y.

Int J Numer Method Biomed Eng. 2016 Jan;32(1):e02734. doi: 10.1002/cnm.2734. Epub 2015 Aug 19.

45.

The role of cytoreductive surgery in the era of targeted agents.

Noe A, Stewart GD, Bex A.

Curr Opin Urol. 2015 Sep;25(5):374-80. doi: 10.1097/MOU.0000000000000192. Review.

PMID:
26075568
46.

Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, Riddick AC, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T.

Clin Cancer Res. 2015 Sep 15;21(18):4212-23. doi: 10.1158/1078-0432.CCR-15-0207. Epub 2015 May 26.

47.

Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer.

Stewart GD, Riddick AC, Rae F, Marshall C, MacLeod L, O'Mahony FC, Laird A, Alan McNeill S, O'Connor KM, O'Donnell M, Fineron P, McLaren DB, Aitchison M, Oades G, Hair J, Seywright M, Little B, Nairn R, Lamb G, Macleod T, Dunn I, Ramsey A, Campbell R, Leung S, McLornan L, Rahilly M, Wilson I, Pollock AM, Harrison DJ.

Surgeon. 2015 Aug;13(4):181-6. doi: 10.1016/j.surge.2015.03.001. Epub 2015 Apr 30.

PMID:
25937514
48.

Observations on transatlantic renal cell cancer surgery outcomes.

Stewart GD, Laird A, McNeill SA, Leibovich BC.

BJU Int. 2016 Feb;117(2):212-4. doi: 10.1111/bju.13117. Epub 2015 May 13. No abstract available.

49.

Consultation audio-recording reduces long-term decision regret after prostate cancer treatment: A non-randomised comparative cohort study.

Good DW, Delaney H, Laird A, Hacking B, Stewart GD, McNeill SA.

Surgeon. 2016 Dec;14(6):308-314. doi: 10.1016/j.surge.2014.10.006. Epub 2015 Jan 28.

PMID:
25636362
50.

A Critical Analysis of the Learning Curve and Postlearning Curve Outcomes of Two Experience- and Volume-Matched Surgeons for Laparoscopic and Robot-Assisted Radical Prostatectomy.

Good DW, Stewart GD, Laird A, Stolzenburg JU, Cahill D, McNeill SA.

J Endourol. 2015 Aug;29(8):939-47. doi: 10.1089/end.2014.0810. Epub 2015 Feb 25.

PMID:
25630790

Supplemental Content

Loading ...
Support Center